Clasado and Probi's new synbiotic concept increases production of lactate and short-chain fatty acids to provide superior benefits when combined, according to new research.
The two new synbiotic formulations are the first launches since the Swedish probiotics player and the British prebiotic innovator announced a partnership in the summer to develop health-promoting synbiotic products.
Subscribe
Growing in APAC: Swedish probiotic firm Probi expands China market via new deal with Sinopharm Foreign Trade By Tingmin Koe Swedish probiotic firm Probi is expanding its presence in APAC via a new deal with China National Pharmaceutical Foreign Trade Corporation (Sinopharm Foreign Trade).
Established in 1981, Sinopharm Foreign Trade is a wholly-owned subsidiary of China National Pharmaceutical Group Corporation, also widely known as Sinopharm – one of the China companies that have successfully developed COVID-19 vaccines.
Under the partnership, Sinopharm Foreign Trade will be launching probiotic products for immune health, bone health, and iron absorption with probiotic strains backed by Probi’s research and clinical data.
Probiotics can benefit repeat cold sufferers: RCT Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2 can reduce the incidence but not severity of colds in people prone to catching colds, a Swedish study has found.
The Lund University trial built on other studies using Probi’s Defendum proprietary probiotic blend, but here the key difference was a population highly prone to catching the common cold – the world’s most common infectious disease.
Adults typically average 1-3 colds per year, children 4-6 – here the sample of about 900 otherwise healthy 18-70-year-old Germans had caught at least four physician-validated colds in a 12-month period before each of the three winter seasons of the trial.